What is a tumour?
A tumour is uncontrolled cell growth that forms a mass. Tumours are divided into benign and malignant. Benign tumours are not cancerous — they grow slowly and do not spread to other parts of the body. Malignant tumours are cancerous: they can invade surrounding tissue and, through the blood or lymph, reach other sites in the body. This process is called metastasis.
What is cancer?
Cancer is a disease driven by the uncontrolled multiplication and spread of altered cells. There are many kinds of cancer: breast, lung, colon, prostate, skin and many more. The type of cancer is defined by the original source of the altered cells. For example, if breast-cancer cells reach the lungs, the secondary tumour is still considered breast cancer, not lung cancer.
The challenge of metastatic cancer
Metastatic cancer is one of the hardest treatment challenges, because the disease has already spread to other parts of the body. Symptoms depend on the type of the primary tumour and the location of the metastases, but most often they include fatigue, weight loss and pain. Some forms of cancer, such as skin cancer, are diagnosed more easily; others — such as bone cancer — are rarer and harder to manage. This is precisely why supporting the immune system matters so much: a strong immune system can help recognise altered cells before they spread. Proper nutrition, reducing inflammation in the body, and supporting mitochondrial function are factors we can control ourselves.
How cancer spreads through metastasis
Metastasis is the process in which cancer cells leave the primary tumour, travel to another part of the body, and create a secondary tumour there. The cells spread through the circulatory or the lymphatic system. It is for this very reason that early diagnosis and constant support of the immune system are so important.
Treating a tumour
Treating a tumour depends on many factors, including the type of cancer, its location, its size and the stage of its spread. The methods of treatment may include:
Surgery: Depending on the type of cancer, a carcinoma may be removed by operation, taking out the cancerous cells and the surrounding areas of tissue. Minimally invasive surgical methods help shorten recovery time and reduce the risk of complications.
Radiotherapy (radiation treatment): Radiotherapy may be used together with surgical or chemotherapeutic treatment. Advanced technologies in this treatment make it possible to keep watch on tumour growth even after therapy. This therapy uses X-rays and gamma rays, and radioactive substances delivered intravenously may also be used. Radiotherapy can raise the risk of cancer recurring [1]. The side effects of this therapy depend on the dose and may appear soon afterwards or later, from a few months to a few years [2]. The most common side effect is weakness, though side effects differ depending on the type of cancer [3]. Even so, the side effects of radiotherapy are usually less intense than those of chemotherapy.
Chemotherapy: This is one of the most common ways to treat cancer. These are anti-cancer drugs that act on rapidly multiplying cells throughout the whole body or in a particular area.
Fighting tumours: additional measures
It is worth knowing that alcohol can be a negative factor in the fight against tumours, because it is toxic to cells. Drinking alcohol can deepen existing damage and have an unwanted effect. It is therefore advisable to avoid drinking alcohol [6].
It has long been known that mushrooms hold an unrivalled variety of pharmacological properties and can be used as medicine. Lentinan is held in especially high regard — a substance widely studied and known for its anti-cancer properties. Lentinan, acting through the immune system, can stimulate immune cells such as cytokines, macrophages and natural killer cells, which may help the body fight cancer cells [7].
Scientific reviews show that mushroom polysaccharides activate NK cells, macrophages and T-lymphocytes — the key immune cells responsible for recognising and destroying altered cells [4][5]. Lentinan AXT from Zenius Labs™ is a concentrated formula of several mushroom-polysaccharide extracts, designed for this purpose.
Frequently Asked Questions
A tumour is an unusual growth of cells in the body. Tumours may be benign (not dangerous) or malignant (cancerous). Malignant tumours can spread to other organs — this is called metastasis.
Yes. The immune system is the main defence against altered cells. Mushroom polysaccharides can help activate NK cells and macrophages, which recognise and destroy tumour cells. It is important to choose a concentrated multi-extract formula, such as Lentinan AXT from Zenius Labs™.
A benign tumour grows slowly, does not spread to other organs and is usually not life-threatening. A malignant tumour (cancer) grows faster, can invade surrounding tissue and metastasise — spreading through the blood or lymph to distant parts of the body.
The symptoms depend on the location and type of the tumour. Common signs are a lump of unclear origin, unexplained weight loss, constant fatigue, pain and unusual bleeding. Regular preventive check-ups help diagnose a tumour early.
Treatment depends on the type, stage and location. The most common methods are surgery, chemotherapy, radiotherapy and immunotherapy. Supporting the immune system during and after treatment is very important for recovery.
- What is cancer? Cancer.org Source
- What is cancer? Cancer.gov Source
- Understanding cancer. Cancer.org Source
- Antitumor polysaccharides from mushrooms: structural characteristics, antitumor mechanisms and immunomodulating activities. PubMed
- Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. PubMed
- Wang H et al. Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta-analysis. Cancer medicine . 2017. PubMed
- Wang Y et al. Systematic review and meta-analysis on the efficacy and safety of Injectable Lentinan combined with chemotherapy in the treatment of gastric cancer. Phytomedicine : international journal of phytotherapy and phytopharmacology . 2024. PubMed
- Oba K et al. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer. Anticancer research . 2009. PubMed
- Gringhuis SI et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nature immunology . 2009. PubMed
- Jia XM et al. CARD9 mediates Dectin-1-induced ERK activation by linking Ras-GRF1 to H-Ras for antifungal immunity. The Journal of experimental medicine . 2014. PubMed
- Cheng SC et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science (New York, N.Y.) . 2014. PubMed
- Zhou G et al. Lentinan progress in inflammatory diseases and tumor diseases. European journal of medical research . 2024. PubMed
- Deng S et al. Lentinan inhibits tumor angiogenesis via interferon γ and in a T cell independent manner. Journal of experimental & clinical cancer research : CR . 2018. PubMed
- You J et al. Lentinan induces apoptosis of mouse hepatocellular carcinoma cells through the EGR1/PTEN/AKT signaling axis. Oncology reports . 2023. PubMed
- Amino M et al. [Studies on the effect of lentinan on human immune system. II. In vivo effect on NK activity, MLR induced killer activity and PHA induced blastic response of lymphocytes in cancer patients]. Gan to kagaku ryoho. Cancer & chemotherapy . 1983. PubMed
- Zhen C et al. Comprehensive mechanisms and advanced delivery strategies of lentinan in antitumor therapy: A review. Colloids and surfaces. B, Biointerfaces . 2026. PubMed
- Chihara G Recent progress in immunopharmacology and therapeutic effects of polysaccharides. Developments in biological standardization . 1992. PubMed
- Oba K et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer immunology, immunotherapy : CII . 2007. PubMed
- Lu H et al. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clinical cancer research : an official journal of the American Association for Cancer Research . 2011. PubMed
- Engel AL et al. Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant. Immunobiology . 2013. PubMed
- Tanaka H et al. Impact of adjuvant immunochemotherapy using protein-bound polysaccharide-K on overall survival of patients with gastric cancer. Anticancer research . 2012. PubMed
- Chang Y et al. Preclinical and clinical studies of Coriolus versicolor polysaccharopeptide as an immunotherapeutic in China. Discovery medicine . 2017. PubMed
- Standish LJ et al. Trametes versicolor mushroom immune therapy in breast cancer. Journal of the Society for Integrative Oncology . 2008. PubMed
- Kidd P Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging potential. Alternative medicine review : a journal of clinical therapeutic . 2011. PubMed
- Copat C et al. Astaxanthin in cancer therapy and prevention (Review). Biomedical reports . 2025. PubMed
- Li J et al. Astaxanthin Inhibits Proliferation and Induces Apoptosis of Human Hepatocellular Carcinoma Cells via Inhibition of Nf-Κb P65 and Wnt/Β-Catenin in Vitro. Marine drugs . 2015. PubMed
- Lee J et al. Anti-Oxidant and Anti-Inflammatory Effects of Astaxanthin on Gastrointestinal Diseases. International journal of molecular sciences . 2022. PubMed
- Saini RK et al. Dietary carotenoids in cancer chemoprevention and chemotherapy: A review of emerging evidence. Pharmacological research . 2020. PubMed
- Geller AE et al. The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression. Nature communications . 2022. PubMed
- Dan A et al. Therapeutic Effects of Medicinal Mushrooms on Gastric, Breast, and Colorectal Cancer: A Scoping Review. Cureus . 2023. PubMed